Abstract
A key challenge in pulmonary gene therapy for cystic fibrosis is to provide long-term correction of the genetic defect. This may be achievable by targeting airway epithelial stem/progenitor cells with an integrating vector. Here, we evaluated the ability of a lentiviral vector, derived from the simian immunodeficiency virus and pseudotyped with F and HN envelope proteins from Sendai virus, to transduce progenitor basal cells of the mouse nasal airways. We first transduced basal cell-enriched cultures ex vivo and confirmed efficient transduction of cytokeratin-5 positive cells. We next asked whether progenitor cells could be transduced in vivo. We evaluated the transduction efficiency in mice pretreated by intranasal administration of polidocanol to expose the progenitor cell layer. Compared to control mice, polidocanol treated mice demonstrated a significant increase in the number of transduced basal cells at 3 and 14 days post vector administration. At 14 days, the epithelium of treated mice contained clusters (4 to 8 adjacent cells) of well differentiated ciliated, as well as basal cells suggesting a clonal expansion. These results indicate that our lentiviral vector can transduce progenitor basal cells in vivo, although transduction required denudation of the surface epithelium prior to vector administration.
Keywords: Cystic fibrosis, Gene therapy, Lentivirus, Progenitor basal cells, Polidocanol.
Current Gene Therapy
Title:Ex Vivo and In Vivo Lentivirus-Mediated Transduction of Airway Epithelial Progenitor Cells
Volume: 15 Issue: 6
Author(s): Giulia Leoni, Marguerite Y. Wasowicz, Mario Chan, Cuixiang Meng, Raymond Farley, Steven L. Brody, Makoto Inoue, Mamoru Hasegawa, Eric W.F.W. Alton and Uta Griesenbach
Affiliation:
Keywords: Cystic fibrosis, Gene therapy, Lentivirus, Progenitor basal cells, Polidocanol.
Abstract: A key challenge in pulmonary gene therapy for cystic fibrosis is to provide long-term correction of the genetic defect. This may be achievable by targeting airway epithelial stem/progenitor cells with an integrating vector. Here, we evaluated the ability of a lentiviral vector, derived from the simian immunodeficiency virus and pseudotyped with F and HN envelope proteins from Sendai virus, to transduce progenitor basal cells of the mouse nasal airways. We first transduced basal cell-enriched cultures ex vivo and confirmed efficient transduction of cytokeratin-5 positive cells. We next asked whether progenitor cells could be transduced in vivo. We evaluated the transduction efficiency in mice pretreated by intranasal administration of polidocanol to expose the progenitor cell layer. Compared to control mice, polidocanol treated mice demonstrated a significant increase in the number of transduced basal cells at 3 and 14 days post vector administration. At 14 days, the epithelium of treated mice contained clusters (4 to 8 adjacent cells) of well differentiated ciliated, as well as basal cells suggesting a clonal expansion. These results indicate that our lentiviral vector can transduce progenitor basal cells in vivo, although transduction required denudation of the surface epithelium prior to vector administration.
Export Options
About this article
Cite this article as:
Leoni Giulia, Y. Wasowicz Marguerite, Chan Mario, Meng Cuixiang, Farley Raymond, L. Brody Steven, Inoue Makoto, Hasegawa Mamoru, W.F.W. Alton Eric and Griesenbach Uta, Ex Vivo and In Vivo Lentivirus-Mediated Transduction of Airway Epithelial Progenitor Cells, Current Gene Therapy 2015; 15 (6) . https://dx.doi.org/10.2174/1566523215666151016123625
DOI https://dx.doi.org/10.2174/1566523215666151016123625 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Sphingosine 1-Phosphate in Vascular Biology: Possible Therapeutic Strategies to Control Vascular Diseases
Current Pharmaceutical Design MicroRNAs and Physical Activity
MicroRNA Adrenomedullin: Roles for Structure and Function in Cardiac or Vascular Tissues
Current Hypertension Reviews Systematic Review of the Role of Microparticles in Systemic Sclerosis
Current Rheumatology Reviews Protease-Activated Receptors (PARs) are Partly Pro-Inflammatory and Partly Anti-Inflammatory: Will PAR Agonists or Antagonists Participate in Future Drug Therapies?
Current Drug Targets Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Synthesis and Evaluation of Indole Based Molecules for Treatment of Oxidative Stress Related Diseases
Current Topics in Medicinal Chemistry Intra - and Intercellular Calcium Handling in Pulmonary Arterial Hypertension
Medicinal Chemistry G Protein-Coupled Receptors and their Signaling Pathways: Classical Therapeutical Targets Susceptible to Novel Therapeutic Concepts
Current Pharmaceutical Design Ambient Pollution and COPD
Current Respiratory Medicine Reviews Recent Advances in Synthesis of PAR Ligands as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry Lung Structural Changes in Chronic Obstructive Pulmonary Diseases
Current Drug Targets - Inflammation & Allergy Tachykinins and the Cardiovascular System
Current Drug Targets Pharmacological and Cellular Therapies to Prevent Restenosis after Percutaneous Transluminal Angioplasty and Stenting
Cardiovascular & Hematological Agents in Medicinal Chemistry An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes
Current Drug Targets Exogenous Surfactant in Paediatric Acute Lung Injury and Acute Respiratory Distress Syndrome
Current Drug Safety Induced Adaptive Resistance to Oxidative Stress in the CNS: A Discussion on Possible Mechanisms and Their Therapeutic Potential
Current Drug Metabolism Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Effect of Simvastatin on Inflammatory Cytokines Balance in Air Pouch Granuloma Model
Inflammation & Allergy - Drug Targets (Discontinued)